Products
Porustobart Biosimilar VH-Fc Antibody (CTLA-4) for Research
Cat No.: GMP-Bios-INN-1340
Anti-CTLA4/CD152 therapeutic antibody (Pre-made Porustobart biosimilar,VH-CH2-CH3) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Porustobart (development code HBM-4003) is a VH-CH2-CH3 domain antibody targeting CTLA-4. It is developed by Harbour Biomed for Solid tumours in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1340-1mg | 1mg | 3090 |
| GMP-Bios-INN-1340-10mg | 10mg | |
| GMP-Bios-INN-1340-100mg | 100mg | |
| GMP-Bios-INN-1340-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Porustobart biosimilar, VH-CH2-CH3, Anti-CTLA4/CD152 Antibody: Anti-CTLA-4/CD152/CTLA4/Cytotoxic T-lymphocyte protein 4 therapeutic antibody |
| INN Name | Porustobart |
| Target | CTLA4/CD152 |
| Format | VH-CH2-CH3 |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 7dv4:H:B:D:F |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Harbour Biomed |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
